- Home
- DOUG vs SGMT Comparison
DOUG vs SGMT Comparison
Compare DOUG & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOUG
- SGMT
- Stock Information
- Founded
- DOUG 1911
- SGMT 2006
- Country
- DOUG United States
- SGMT United States
- Employees
- DOUG N/A
- SGMT N/A
- Industry
- DOUG Building operators
- SGMT
- Sector
- DOUG Real Estate
- SGMT
- Exchange
- DOUG Nasdaq
- SGMT Nasdaq
- Market Cap
- DOUG 142.2M
- SGMT 159.0M
- IPO Year
- DOUG N/A
- SGMT 2023
- Fundamental
- Price
- DOUG $1.79
- SGMT $4.39
- Analyst Decision
- DOUG
- SGMT Buy
- Analyst Count
- DOUG 0
- SGMT 6
- Target Price
- DOUG N/A
- SGMT $23.00
- AVG Volume (30 Days)
- DOUG 1.0M
- SGMT 1.2M
- Earning Date
- DOUG 02-27-2025
- SGMT 11-13-2024
- Dividend Yield
- DOUG N/A
- SGMT N/A
- EPS Growth
- DOUG N/A
- SGMT N/A
- EPS
- DOUG N/A
- SGMT N/A
- Revenue
- DOUG $966,442,000.00
- SGMT N/A
- Revenue This Year
- DOUG $5.28
- SGMT N/A
- Revenue Next Year
- DOUG $16.40
- SGMT N/A
- P/E Ratio
- DOUG N/A
- SGMT N/A
- Revenue Growth
- DOUG 1.86
- SGMT N/A
- 52 Week Low
- DOUG $1.00
- SGMT $2.39
- 52 Week High
- DOUG $2.98
- SGMT $20.71
- Technical
- Relative Strength Index (RSI)
- DOUG 51.94
- SGMT 44.30
- Support Level
- DOUG $1.49
- SGMT $4.06
- Resistance Level
- DOUG $1.84
- SGMT $7.38
- Average True Range (ATR)
- DOUG 0.12
- SGMT 0.63
- MACD
- DOUG 0.04
- SGMT -0.11
- Stochastic Oscillator
- DOUG 75.95
- SGMT 9.94
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).